Member Since 2021
Cocoon Biotech Inc.
Dr. Ailis Tweed-Kent is an entrepreneur and leader in the development of innovative technologies. She is passionate about the intersection of health and the environment and brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame, an M.D. at Harvard Medical School, and training in internal medicine at Massachusetts General Hospital. In 2013, Ailis was inspired by her patients to found Cocoon to develop silk as a sustainable materials science platform. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as the London School of Hygiene & Tropical Medicine and the Doris Duke Charitable Foundation. She was named to the Boston Business Journal’s 2017 Women to Watch in Science and Technology as well as the Boston MedTech’s 40 Under 40 Healthcare Innovators.
Cocoon Biotech, Inc., was founded in 2013 to bring the freedom of living a healthy productive life to patients worldwide. Cocoon Biotech is developing a drug-delivery platform based on formulations of fibroin, a protein derived from the cocoon of the silkworm (Bombyx mori). Recent advances in our understanding of fibroin biochemistry has allowed expansion of the versatility of the material into alternate physical formats such as hydrogels and implants loaded with active drug substances. Cocoon is leveraging silk fibroin as a novel biomaterial for the stability and delivery of therapeutics across human health and animal health. Cocoon’s first products are silk fibroin formulated with small molecules that target pain and inflammation in ophthalmology and osteoarthritis indications.